secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001558370-23-000894
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros receives $200M milestone payment from Rayner; 2022 OMIDRIA sales $131M
-----------------------------------------------------------------------------

- Rayner paid $200M milestone plus accrued interest on Feb 3, 2023; U.S. royalty rate drops from 50% to 30%.
- Omeros ended 2022 with ~$195M cash; combined with $200M milestone provides funding into at least 2025.
- 2022 U.S. net sales of OMIDRIA totaled $131M; CAA 2023 secures separate payment for non-opioid pain drugs through Jan 2028.
- Proceeds to fund R&D, manufacturing, potential acquisitions; may retire convertible notes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837023000894/0001558370-23-000894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837023000894/omer-20230206x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-000894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer